Literature DB >> 12843235

Quantitative accuracy of dopaminergic neurotransmission imaging with (123)I SPECT.

Marine Soret1, Pierre Malick Koulibaly, Jacques Darcourt, Sébastien Hapdey, Irène Buvat.   

Abstract

UNLABELLED: 123I-Labeled radiotracers are suitable for in vivo imaging of the dopaminergic system by SPECT. However, precise measurement of striatal uptake is limited by scatter, attenuation, and the finite spatial resolution of the camera. We studied the quantitative accuracy that can be achieved with (123)I SPECT of the dopaminergic neurotransmission system.
METHODS: Using a Monte Carlo simulation and brain phantom experiments, we studied the biases in brain and striatal absolute uptake estimates and in binding potential (BP) values for different processing schemes with corrections for attenuation, scatter, and the partial-volume effect.
RESULTS: Without any correction, brain activity was underestimated by at least 65%, and absolute striatal activity measured in regions corresponding to the anatomic contours of the striata was underestimated by about 90%. With scatter and attenuation corrections only, estimated brain activity was accurate within 10%; however, striatal activity remained underestimated by about 50%, and BP values were underestimated by more than 50%. When combined with attenuation and scatter corrections, anatomically guided partial-volume effect correction (PVC) reduced the biases in striatal activity estimates and in BP values to about 10%. PVC reliability was affected by errors in registering SPECT with anatomic images, in segmenting anatomic images, and in estimating the spatial resolution. With registration errors of 1 voxel (2.1 x 2.1 x 3.6 mm(3)) in all directions and of 15 degrees around the axial direction, PVC still improved the accuracy of striatal activity and BP estimates compared with scatter and attenuation corrections alone, the errors being within 25%. A 50% overestimation of the striatal volume yielded an approximate 30% change in striatal activity estimates with respect to no overestimation but still provided striatal activity estimates that were more accurate than those obtained without PVC (average errors +/- 1 SD were -22.5% +/- 1.0% with PVC and -49.0% +/- 5.5% without PVC). A 2-mm error in the spatial resolution estimate changed the striatal activity and BP estimates by no more than 10%.
CONCLUSION: Accurate estimates of striatal uptake and BP in (123)I brain SPECT are feasible with PVC, even with small errors in registering SPECT with anatomic data or in segmenting the striata.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12843235

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

2.  Effect of scatter correction on the compartmental measurement of striatal and extrastriatal dopamine D2 receptors using [123I]epidepride SPET.

Authors:  Masahiro Fujita; Andrea Varrone; Kyeong Min Kim; Hiroshi Watabe; Sami S Zoghbi; Nicholas Seneca; Dnyanesh Tipre; John P Seibyl; Robert B Innis; Hidehiro Iida
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-01-17       Impact factor: 9.236

3.  Proposal for the standardisation of multi-centre trials in nuclear medicine imaging: prerequisites for a European 123I-FP-CIT SPECT database.

Authors:  John Caddell Dickson; Livia Tossici-Bolt; Terez Sera; Robin de Nijs; Jan Booij; Maria Claudia Bagnara; Anita Seese; Pierre Malick Koulibaly; Umit Ozgur Akdemir; Cathrine Jonsson; Michel Koole; Maria Raith; Markus Nowak Lonsdale; Jean George; Felicia Zito; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01       Impact factor: 9.236

4.  Anatomical-based partial volume correction for low-dose dedicated cardiac SPECT/CT.

Authors:  Hui Liu; Chung Chan; Yariv Grobshtein; Tianyu Ma; Yaqiang Liu; Shi Wang; Mitchel R Stacy; Albert J Sinusas; Chi Liu
Journal:  Phys Med Biol       Date:  2015-08-21       Impact factor: 3.609

5.  PET is better than perfusion SPECT for early diagnosis of Alzheimer's disease -- against.

Authors:  Alberto Pupi; Flavio Mariano Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12       Impact factor: 9.236

6.  A publicly accessible Monte Carlo database for validation purposes in emission tomography.

Authors:  I Castiglioni; I Buvat; G Rizzo; M C Gilardi; J Feuardent; F Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-07-02       Impact factor: 9.236

7.  Cross-camera comparison of SPECT measurements of a 3-D anthropomorphic basal ganglia phantom.

Authors:  Walter Koch; Perry E Radau; Wolfgang Münzing; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-01-25       Impact factor: 9.236

8.  The impact of reconstruction method on the quantification of DaTSCAN images.

Authors:  John C Dickson; Livia Tossici-Bolt; Terez Sera; Kjell Erlandsson; Andrea Varrone; Klaus Tatsch; Brian F Hutton
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

9.  Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database.

Authors:  Livia Tossici-Bolt; John C Dickson; Terez Sera; Robin de Nijs; Maria Claudia Bagnara; Catherine Jonsson; Egon Scheepers; Felicia Zito; Anita Seese; Pierre Malick Koulibaly; Ozlem L Kapucu; Michel Koole; Maria Raith; Jean George; Markus Nowak Lonsdale; Wolfgang Münzing; Klaus Tatsch; Andrea Varrone
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-06       Impact factor: 9.236

10.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.